Low dose methotrexate treatment in adult Still's disease.
Six patients with adult Still's disease who had either failed to respond to or had adverse effects from previous therapy were given weekly low dose methotrexate (MTX) therapy. They were followed for 4-28 months (mean 14 +/- 9 months). At 12 months of therapy 3 patients were evaluated as having a complete response. One patient had a partial response to MTX after 7 months. Therapy was discontinued in 1 patient at 4 months due to flares of rash and arthralgias after each MTX administration. One patient failed to respond to therapy despite maximum dosage, but was able to reduce his corticosteroid dose. MTX may be a useful therapy to consider in patients with adult Still's disease who are resistant to conventional therapy and may allow a reduction in the concomitant dose of corticosteroids.
Aydintug
A O
AO
Lupus Arthritis Research Unit, Rayne Institute, St. Thomas' Hospital, London, UK.
D'Cruz
D
D
Cervera
R
R
Khamashta
M A
MA
Hughes
G R
GR
D000328:Adult; D001799:Blood Sedimentation; D004305:Dose-Response Relationship, Drug; D005260:Female; D006261:Headache / Q000139:chemically induced; D006801:Humans; D007958:Leukocyte Count / Q000187:drug effects; D008297:Male; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D009059:Mouth Diseases / Q000139:chemically induced; D011239:Prednisolone / Q000627:therapeutic use; D016706:Still's Disease, Adult-Onset / Q000188:drug therapy* / Q000503:physiopathology; D014456:Ulcer / Q000139:chemically induced
D011239:Prednisolone; D008727:Methotrexate